Mylan Recalls a Second Batch of Insulin Glargine
This is the second batch to be recalled because of the potential of missing labels.
Mylan Pharmaceuticals, a Viatris company, is recalling another batch of Insulin Glargine (insulin glargine-yfgn) injection, this time 3 mL prefilled pens packaged in cartons of five pens. This is not the branded Semglee pen but the unbranded Insulin Glargine-yfgn pens. This batch is being recalled due to the potential for the label to be missing on some pens.
Mylan notes that a missing label could lead to a mix-up of products/strengths, which may result in less optimal glycemic control. To date, no adverse events related to this recall have been received for this product.
In April 2022, Mylan recalled one batch of its insulin glargine injection packaged in a carton with 10 mL vials for the same reason.
Related: Mylan Recalls One Batch of Insulin Glargine
The impacted product is this current recall is batch number BF21002895 with an expiration date of August 2023. The NDC number is 49502-394-75. This batch was manufactured by Biocon Sdn. and was distributed by Mylan Specialty in the United States between April 4, 2022, and May 5, 2022.
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More
